{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-129592","form_type":"8-K","ticker":"ESPR","cik":"0001434868","company_name":"Esperion Therapeutics, Inc.","filed_at":"2024-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.444811+00:00","generated_at":"2026-05-29T01:57:51.669857+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Esperion completes $100M convertible note issuance and exchange of 2025 notes","bullets":["Issued $100M aggregate principal of 5.75% Convertible Senior Subordinated Notes due June 15, 2030.","Exchanged ~$210.1M of existing 4.00% 2025 Notes for ~$57.5M new notes plus ~$153.4M cash.","Sold ~$42.5M of new notes for cash; net proceeds for general corporate purposes.","Initial conversion rate 326.7974 shares per $1,000 principal, conversion price ~$3.06 per share.","New notes are senior unsecured, redeemable after Dec 20, 2027 under certain conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-129592","json":"https://secwatch.observer/filing/0001104659-24-129592.json","markdown":"https://secwatch.observer/filing/0001104659-24-129592.md","text":"https://secwatch.observer/filing/0001104659-24-129592.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434868/000110465924129592/0001104659-24-129592-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434868/000110465924129592/tm2430949d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T01:57:51.669857+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}